PRESS RELEASE

PRESS RELEASE

Jul 01, 2020

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

SHANGHAI, CHINA and PHILADELPHIA, U.S. July 1, 2020 — Antengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice ...

Jun 08, 2020

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

SHANGHAI and HONG KONG, China—June 8, 2020—Antengene Corporation (Antengene) today announced its appointment of Mr. Donald Lung as Chief Financial...

May 05, 2020

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

SHANGHAI, China – May 5, 2020 – Antengene Corporation (Antengene) today announced a broadened partnership and territory expansion agreement with K...

Apr 27, 2020

Antengene Doses First Patient with ATG-008, a mTOR1/2 Dual-targeted Inhibitor, for Advanced Solid Tumors and Hepatocellular Carcinoma of the Clinical Trial with Junshi Biosciences’ Toripalimab

SHANGHAI, China and PHILADELPHIA, U.S.- April 27, 2020 – Antengene Corporation announced today that it has dosed the first patient with advanced...

Apr 24, 2020

Antengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

SHANGHAI, China and PHILADELPHIA, U.S. — April 24, 2020 — Antengene announced today that it has dosed the first patient in a registration trial in...

Apr 13, 2020

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

SHANGHAI, CHINA and MELBOURNE, AUSTRALIA – April 13, 2020 – Antengene Corporation today announced the appointment of Mr. Thomas Karalis as...

Apr 13, 2020

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma

Shanghai, China and Philadelphia, U.S. — April 13, 2020 — Antengene announced today that it has dosed the first patient in Taiwan, China i...

Mar 12, 2020

Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Shanghai, China and Philadelphia, U.S. — March 12, 2020 — Antengene announced the launch of a clinical trial of ATG-010 in patients with K...

Mar 12, 2020

Phase 2 clinical trial of ATG-008 as targeted therapy for advanced non-small-cell lung cancer initiated in China

Shanghai, China and Philadelphia, U.S. — March 12, 2020 — Antengene announced the launch of a clinical trial of ATG-008 for the treatment ...

Mar 09, 2020

Clinical trial of Antengene’s ATG-008 in combination with Junshi Biosciences’ Toripalimab for treatment of advanced solid tumors and hepatocellular carcinoma officially initiated

– ATG-008 is a new generation mTORC1 / 2 dual-targeted inhibitor – This trial is an open-label, incremental and expanded study to evaluat...

Mar 03, 2020

Phase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint

– Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Signific...

Mar 02, 2020

Novel oral medication for diffuse large B-cell lymphoma! Another indication of XPOVIO®, a first-in-class nuclear export inhibitor, is expected to achieve accelerated approval

Antengene’s partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that the U.S. Food and Drug Administration has accepted for filing its sup...

Jan 25, 2020

News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved

Antengene announced today that NMPA has approved the clinical trial application of ATG-010 for relapsed or refractory peripheral T and NK/T-cell lymph...

Jan 16, 2020

Antengene Presented a Keynote Speech at J.P. Morgan Conference

San Francisco, U.S. and Shanghai, CHINA, January 15, 2020–Dr. Jay Mei, Chairman & CEO of Antengene Corporation, presented a keynote speech ...

Jan 08, 2020

Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors

SHANGHAI, CHINA and PHILADELPHIA, U.S. – – January 8, 2020 – -The Antengene board today announced the appointment of Mr. Mark J. All...

Jan 06, 2020

Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer

SHANGHAI, CHINA and PHILADELPHIA, U.S. — January 6, 2020—Antengene Corporation today announced its appointment of Mr. John Chin, MBA, as Chief...

Jan 03, 2020

News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China

Shanghai, China — Antengene Corporation announced on January 3, 2020 that the Food and Drug Administration, Ministry of Health and Welfare, Taiwan (...

Nov 06, 2019

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

SHANGHAI, CHINA and LONDON, U.K. — November 6, 2019 – Antengene Corporation today announced that it has entered into a licensing agreement wit...

Oct 18, 2019

Take the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition

Treating Patients Beyond Borders! Scientific and Technological Innovations Make Great Achievements! On Oct 18th, the final of the Eighth China I...

Sep 19, 2019

Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export

On September 19, 2019, a conference on the latest academic progress in the treatment of multiple myeloma and diffuse large B-cell lymphoma with AT...

Jul 03, 2019

Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

— XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA — XPOVIO is the First and Only Prescription Medicine Appro...

Jun 22, 2019

Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor

SHANGHAI and SHAOXING, China – On June 22, 2018, Antengene announced that ATG-008, its innovative drug for the treatment of advanced hepatocellu...

Apr 28, 2019

Strong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat a

SHANGHAI, China – On April 28, 2019, Antengene announced a strategic partnership with Junshi Biosciences (1877. HK, 833330.OC) to conduct a clin...

Apr 08, 2019

Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute

SHANGHAI, China and PHILADELPHIA, Pennsylvania – April 8, 2019 – Antengene Corporation, a clinical and commercial stage biopharmaceutical company ...

Feb 13, 2019

Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship

SHANGHAI and SHAOXING, China, Feb 13, 2019—Recently, the Science and Technology Department of Zhejiang Province announced the list of “2018 le...

Jan 29, 2019

ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma

SHANGHAI, China – Antengene announced recently that ATG-010, a new Category I drug developed by the company to treat patients with relapsed and/...

Jan 02, 2019

Antengene Corporation Raises $120 Million in Series B Financing

SHANGHAI and SHAOXING, China, Jan. 2, 2019 — Antengene Corporation (Antengene), a clinical stage therapeutics company focused on oncology, annou...

Dec 05, 2018

Antengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”

SHAOXING and SHANGHAI, China, Dec 5, 2018 (Antengene) —Rencently, the Development Center for Medical Science & Technology of National Health an...

Sep 22, 2018

Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese S

On September 22, 2018, at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Antengene published the cl...

Sep 21, 2018

Antengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology

On September 21, 2018 (Beijing time), Antengene Corporation presented a special report entitled “Novel TORC1/2 Inhibitor for Treatment of Hepatocell...